In this randomized controlled trial, abelacimab led to significantly lower rates of major or clinically relevant nonmajor ...

In this randomized clinical trial, among patients who had an out-of-hospital cardiac arrest, no significant difference was ...

In this randomized trial, intraosseous-first vascular access did not result in higher 30-day survival than intravenous-first ...

In this randomized controlled trial, adjuvant trastuzumab emtansine (T-DM1) reduced invasive disease events in patients with ...

In this randomized controlled trial, a transcatheter tricuspid-valve replacement provided a mortality benefit compared to ...

In this randomized controlled trial, among patients with persistent chylomicronemia, it was found that plozasiran more ...

The number of mpox cases in Africa increased leading up to the first mpox declaration of a Public Health Emergency of ...

Vutrisiran treatment reduced the risk of death and recurrent cardiovascular events compared to placebo in patients with ...

In this randomized controlled trial, cabozantinib significantly improved progression-free survival in patients with ...

In this randomized controlled trial, among patients with atrial fibrillation requiring anticoagulation therapy, asundexian ...

In this randomized controlled trial, insulin alfa efsitora (efsitora) demonstrated noninferiority to degludec in reducing ...

Ponsegromab significantly increased body weight in patients with cancer cachexia and elevated GDF-15 levels compared to ...